 WALTHAM, Mass., Sept. 16, 2021 GLOBE NEWSWIRE -- Repligen Corporation NASDAQ:RGEN, a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately 150 million, comprised of 75 million in cash plus 75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. Avitide is a leading chromatography developer with diverse affinity ligand libraries and best-in-class ligand-to-resin development timelines. 